Buy CryptoMarketsSpotFuturesGOLDEarnEvent Center
More
Gold vs Crypto
Agreement supports development and commercialization of higher-dose, subcutaneous administration strategies for nimacimab SAN DIEGO, Jan. 5, 2026 /PRNewswire/ —Agreement supports development and commercialization of higher-dose, subcutaneous administration strategies for nimacimab SAN DIEGO, Jan. 5, 2026 /PRNewswire/ —

Halozyme and Skye Bioscience Announce Global Collaboration and License Agreement to Evaluate Nimacimab Co-Formulated with ENHANZE® for Obesity

Author: AI Journal
Source: AI Journal
2026/01/05 20:31
6 min read
For feedback or concerns regarding this content, please contact us at crypto.news@mexc.com

Agreement supports development and commercialization of higher-dose, subcutaneous administration strategies for nimacimab

SAN DIEGO, Jan. 5, 2026 /PRNewswire/ — Halozyme Therapeutics, Inc. (Nasdaq: HALO) and Skye Bioscience, Inc. (Nasdaq: SKYE) today announced the companies entered into a non-exclusive global collaboration and license agreement in December 2025. Under the collaboration, Skye has licensed Halozyme’s ENHANZE® drug delivery technology for the development and potential commercialization of a subcutaneous formulation of nimacimab for the treatment of obesity. The collaboration is intended to support Skye’s evaluation of higher nimacimab subcutaneous doses through delivery of larger injection volumes.

“Our collaboration with Skye Bioscience expands the reach of our ENHANZE technology into the growing obesity market, a therapeutic area with significant long-term potential,” said Dr. Helen Torley, President and Chief Executive Officer of Halozyme. “This agreement reinforces the scalability of ENHANZE across diverse indications and supports our strategy to drive sustainable royalty growth with new partnerships and innovations.”

“To fully evaluate nimacimab’s potential, we need to test higher doses and we need a practical way to deliver them subcutaneously,” said Punit Dhillon, President and Chief Executive Officer of Skye. “Partnering with Halozyme to co-formulate nimacimab with ENHANZE gives us a validated approach to evaluate multiple dose-ranging strategies, including in combination with GLP-1 receptor agonists.”

Skye will make milestone payments tied to the achievement of certain development and commercialization events. Halozyme will also be entitled to mid-single digit royalties on net sales of nimacimab developed with ENHANZE® for at least 10 years.

Skye is planning to initiate a Phase 2b clinical trial in obesity for nimacimab with ENHANZE in the middle of 2026. This study will also assess the combination of nimacimab and a GLP-1R agonist.

About Halozyme

Halozyme is a biopharmaceutical company advancing disruptive solutions to improve patient experiences and outcomes for emerging and established therapies.

As the innovators of ENHANZE® drug delivery technology with the proprietary enzyme rHuPH20, Halozyme’s commercially validated solution facilitates the subcutaneous delivery of injected drugs and fluids, reducing treatment burden and improving convenience. ENHANZE® has touched more than one million patient lives through ten commercialized products across over 100 global markets and is licensed to leading pharmaceutical and biotechnology companies including Roche, Takeda, Pfizer, Janssen, AbbVie, Eli Lilly, Bristol-Myers Squibb, argenx, ViiV Healthcare, Chugai Pharmaceutical, Acumen Pharmaceuticals, and Merus N.V.

Halozyme is also developing Hypercon™ to expand the breadth of its drug delivery technology portfolio. Hypercon™ is an innovative microparticle technology that is expected to set a new standard in hyper concentration of drugs and biologics that can reduce the injection volume for the same dosage and expands opportunities for at-home and health care provider administration. The addition of Hypercon™ enhances our ability to transform the patient treatment experience by enabling the creation and delivery of highly concentrated biologics, substantially broadening the scope of therapeutics that can be delivered subcutaneously. The Hypercon™ technology has been licensed to leading biopharmaceutical partners, including Johnson & Johnson, Eli Lilly, and argenx.

Halozyme also develops, manufactures, and commercializes drug-device combination products using advanced auto-injector technologies designed to improve convenience, reliability, and tolerability, enhancing patient comfort and adherence. The Company has two proprietary commercial products, Hylenex® and XYOSTED®, partnered commercial products, and ongoing development programs with Teva Pharmaceuticals and McDermott Laboratories Limited, an affiliate of Viatris Inc.

Halozyme is headquartered in San Diego, CA, with offices in Ewing, NJ; Minnetonka, MN; and Boston, MA. Minnetonka is also the site of its operations facility.

For more information, visit http://www.halozyme.com and connect with us on LinkedIn and Twitter.

About Skye Bioscience

Skye is focused on unlocking new therapeutic pathways for metabolic health through the development of next-generation molecules that modulate G-protein coupled receptors. Skye’s strategy leverages biologic targets with substantial human proof of mechanism for the development of potential first-in-class therapeutics with potential clinical and commercial differentiation. Skye is conducting a Phase 2a clinical trial (ClinicalTrials.gov: NCT06577090) in obesity for nimacimab, a negative allosteric modulating antibody that peripherally inhibits CB1. This study is also assessing the combination of nimacimab and a GLP-1R agonist (Wegovy®). For more information, please visit: www.skyebioscience.com. Connect with us on X and LinkedIn.

Forward-Looking Statements 

In addition to historical information, the statements set forth above include forward-looking statements including, without limitation, statements concerning royalty revenue growth, potential new partnerships and innovations, the possible activity, benefits and attributes of ENHANZE®, the possible method of action of ENHANZE®, its potential application to aid in the dispersion and absorption of other injected therapeutic drugs and statements concerning certain other potential benefits of ENHANZE® including facilitating more rapid delivery and administration of larger volumes of injectable medications through subcutaneous delivery and potentially lowering the treatment burden and improving the treatment experience for patients. These forward-looking statements also include statements regarding the product development and commercialization efforts of Skye (including the potential regulatory approval and launch of nimacimab as a result of such efforts and the potential future market opportunity for such products) and Halozyme’s potential receipt of payments associated with achievement of certain development, regulatory and sales-based milestones, and royalties on sales of commercialized products. These forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. The forward-looking statements are typically, but not always, identified through use of the words “believe,” “enable,” “may,” “will,” “could,” “intends,” “estimate,” “anticipate,” “plan,” “predict,” “probable,” “potential,” “possible,” “should,” “continue” and other words of similar meaning. Actual results could differ materially from the expectations contained in forward-looking statements as a result of several factors, including risks and uncertainties concerning whether development, regulatory and sales-based milestones will be achieved, uncertainties concerning whether collaborative products are ultimately developed, approved or commercialized and the potential future market for such products, unexpected levels of revenue growth, expenditures and costs, unexpected results or delays in development and regulatory review, unexpected regulatory approval requirements, unexpected adverse events or patient outcomes and competitive conditions. These and other factors that may result in differences are discussed in greater detail in Halozyme and Skye’s most recent Annual and Quarterly Reports filed with the Securities and Exchange Commission. Except as required by law, Halozyme and Skye undertake no duty to update forward-looking statements to reflect events after the date of this release.

Contacts

Halozyme
Tram Bui
VP, Investor Relations and Corporate Communications
609-359-3016
tbui@halozyme.com

Skye Investor & Media Relations
ir@skyebioscience.com
(858) 410-0266

LifeSci Advisors
Mike Moyer
mmoyer@lifesciadvisors.com
(617) 308-4306

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/halozyme-and-skye-bioscience-announce-global-collaboration-and-license-agreement-to-evaluate-nimacimab-co-formulated-with-enhanze-for-obesity-302652323.html

SOURCE Halozyme Therapeutics, Inc.

Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact crypto.news@mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.
Tags:
#RWA

You May Also Like

Trump-backed WLFI  launches AgentPay SDK open-source payment toolkit for AI agents

Trump-backed WLFI  launches AgentPay SDK open-source payment toolkit for AI agents

The Trump family has expanded its presence in the crypto community with a major development for artificial intelligence (AI) agents. According to reports, World
Share
Cryptopolitan2026/03/20 19:03
Summarize Any Stock’s Earnings Call in Seconds Using FMP API

Summarize Any Stock’s Earnings Call in Seconds Using FMP API

Turn lengthy earnings call transcripts into one-page insights using the Financial Modeling Prep APIPhoto by Bich Tran Earnings calls are packed with insights. They tell you how a company performed, what management expects in the future, and what analysts are worried about. The challenge is that these transcripts often stretch across dozens of pages, making it tough to separate the key takeaways from the noise. With the right tools, you don’t need to spend hours reading every line. By combining the Financial Modeling Prep (FMP) API with Groq’s lightning-fast LLMs, you can transform any earnings call into a concise summary in seconds. The FMP API provides reliable access to complete transcripts, while Groq handles the heavy lifting of distilling them into clear, actionable highlights. In this article, we’ll build a Python workflow that brings these two together. You’ll see how to fetch transcripts for any stock, prepare the text, and instantly generate a one-page summary. Whether you’re tracking Apple, NVIDIA, or your favorite growth stock, the process works the same — fast, accurate, and ready whenever you are. Fetching Earnings Transcripts with FMP API The first step is to pull the raw transcript data. FMP makes this simple with dedicated endpoints for earnings calls. If you want the latest transcripts across the market, you can use the stable endpoint /stable/earning-call-transcript-latest. For a specific stock, the v3 endpoint lets you request transcripts by symbol, quarter, and year using the pattern: https://financialmodelingprep.com/api/v3/earning_call_transcript/{symbol}?quarter={q}&year={y}&apikey=YOUR_API_KEY here’s how you can fetch NVIDIA’s transcript for a given quarter: import requestsAPI_KEY = "your_api_key"symbol = "NVDA"quarter = 2year = 2024url = f"https://financialmodelingprep.com/api/v3/earning_call_transcript/{symbol}?quarter={quarter}&year={year}&apikey={API_KEY}"response = requests.get(url)data = response.json()# Inspect the keysprint(data.keys())# Access transcript contentif "content" in data[0]: transcript_text = data[0]["content"] print(transcript_text[:500]) # preview first 500 characters The response typically includes details like the company symbol, quarter, year, and the full transcript text. If you aren’t sure which quarter to query, the “latest transcripts” endpoint is the quickest way to always stay up to date. Cleaning and Preparing Transcript Data Raw transcripts from the API often include long paragraphs, speaker tags, and formatting artifacts. Before sending them to an LLM, it helps to organize the text into a cleaner structure. Most transcripts follow a pattern: prepared remarks from executives first, followed by a Q&A session with analysts. Separating these sections gives better control when prompting the model. In Python, you can parse the transcript and strip out unnecessary characters. A simple way is to split by markers such as “Operator” or “Question-and-Answer.” Once separated, you can create two blocks — Prepared Remarks and Q&A — that will later be summarized independently. This ensures the model handles each section within context and avoids missing important details. Here’s a small example of how you might start preparing the data: import re# Example: using the transcript_text we fetched earliertext = transcript_text# Remove extra spaces and line breaksclean_text = re.sub(r'\s+', ' ', text).strip()# Split sections (this is a heuristic; real-world transcripts vary slightly)if "Question-and-Answer" in clean_text: prepared, qna = clean_text.split("Question-and-Answer", 1)else: prepared, qna = clean_text, ""print("Prepared Remarks Preview:\n", prepared[:500])print("\nQ&A Preview:\n", qna[:500]) With the transcript cleaned and divided, you’re ready to feed it into Groq’s LLM. Chunking may be necessary if the text is very long. A good approach is to break it into segments of a few thousand tokens, summarize each part, and then merge the summaries in a final pass. Summarizing with Groq LLM Now that the transcript is clean and split into Prepared Remarks and Q&A, we’ll use Groq to generate a crisp one-pager. The idea is simple: summarize each section separately (for focus and accuracy), then synthesize a final brief. Prompt design (concise and factual) Use a short, repeatable template that pushes for neutral, investor-ready language: You are an equity research analyst. Summarize the following earnings call sectionfor {symbol} ({quarter} {year}). Be factual and concise.Return:1) TL;DR (3–5 bullets)2) Results vs. guidance (what improved/worsened)3) Forward outlook (specific statements)4) Risks / watch-outs5) Q&A takeaways (if present)Text:<<<{section_text}>>> Python: calling Groq and getting a clean summary Groq provides an OpenAI-compatible API. Set your GROQ_API_KEY and pick a fast, high-quality model (e.g., a Llama-3.1 70B variant). We’ll write a helper to summarize any text block, then run it for both sections and merge. import osimport textwrapimport requestsGROQ_API_KEY = os.environ.get("GROQ_API_KEY") or "your_groq_api_key"GROQ_BASE_URL = "https://api.groq.com/openai/v1" # OpenAI-compatibleMODEL = "llama-3.1-70b" # choose your preferred Groq modeldef call_groq(prompt, temperature=0.2, max_tokens=1200): url = f"{GROQ_BASE_URL}/chat/completions" headers = { "Authorization": f"Bearer {GROQ_API_KEY}", "Content-Type": "application/json", } payload = { "model": MODEL, "messages": [ {"role": "system", "content": "You are a precise, neutral equity research analyst."}, {"role": "user", "content": prompt}, ], "temperature": temperature, "max_tokens": max_tokens, } r = requests.post(url, headers=headers, json=payload, timeout=60) r.raise_for_status() return r.json()["choices"][0]["message"]["content"].strip()def build_prompt(section_text, symbol, quarter, year): template = """ You are an equity research analyst. Summarize the following earnings call section for {symbol} ({quarter} {year}). Be factual and concise. Return: 1) TL;DR (3–5 bullets) 2) Results vs. guidance (what improved/worsened) 3) Forward outlook (specific statements) 4) Risks / watch-outs 5) Q&A takeaways (if present) Text: <<< {section_text} >>> """ return textwrap.dedent(template).format( symbol=symbol, quarter=quarter, year=year, section_text=section_text )def summarize_section(section_text, symbol="NVDA", quarter="Q2", year="2024"): if not section_text or section_text.strip() == "": return "(No content found for this section.)" prompt = build_prompt(section_text, symbol, quarter, year) return call_groq(prompt)# Example usage with the cleaned splits from Section 3prepared_summary = summarize_section(prepared, symbol="NVDA", quarter="Q2", year="2024")qna_summary = summarize_section(qna, symbol="NVDA", quarter="Q2", year="2024")final_one_pager = f"""# {symbol} Earnings One-Pager — {quarter} {year}## Prepared Remarks — Key Points{prepared_summary}## Q&A Highlights{qna_summary}""".strip()print(final_one_pager[:1200]) # preview Tips that keep quality high: Keep temperature low (≈0.2) for factual tone. If a section is extremely long, chunk at ~5–8k tokens, summarize each chunk with the same prompt, then ask the model to merge chunk summaries into one section summary before producing the final one-pager. If you also fetched headline numbers (EPS/revenue, guidance) earlier, prepend them to the prompt as brief context to help the model anchor on the right outcomes. Building the End-to-End Pipeline At this point, we have all the building blocks: the FMP API to fetch transcripts, a cleaning step to structure the data, and Groq LLM to generate concise summaries. The final step is to connect everything into a single workflow that can take any ticker and return a one-page earnings call summary. The flow looks like this: Input a stock ticker (for example, NVDA). Use FMP to fetch the latest transcript. Clean and split the text into Prepared Remarks and Q&A. Send each section to Groq for summarization. Merge the outputs into a neatly formatted earnings one-pager. Here’s how it comes together in Python: def summarize_earnings_call(symbol, quarter, year, api_key, groq_key): # Step 1: Fetch transcript from FMP url = f"https://financialmodelingprep.com/api/v3/earning_call_transcript/{symbol}?quarter={quarter}&year={year}&apikey={api_key}" resp = requests.get(url) resp.raise_for_status() data = resp.json() if not data or "content" not in data[0]: return f"No transcript found for {symbol} {quarter} {year}" text = data[0]["content"] # Step 2: Clean and split clean_text = re.sub(r'\s+', ' ', text).strip() if "Question-and-Answer" in clean_text: prepared, qna = clean_text.split("Question-and-Answer", 1) else: prepared, qna = clean_text, "" # Step 3: Summarize with Groq prepared_summary = summarize_section(prepared, symbol, quarter, year) qna_summary = summarize_section(qna, symbol, quarter, year) # Step 4: Merge into final one-pager return f"""# {symbol} Earnings One-Pager — {quarter} {year}## Prepared Remarks{prepared_summary}## Q&A Highlights{qna_summary}""".strip()# Example runprint(summarize_earnings_call("NVDA", 2, 2024, API_KEY, GROQ_API_KEY)) With this setup, generating a summary becomes as simple as calling one function with a ticker and date. You can run it inside a notebook, integrate it into a research workflow, or even schedule it to trigger after each new earnings release. Free Stock Market API and Financial Statements API... Conclusion Earnings calls no longer need to feel overwhelming. With the Financial Modeling Prep API, you can instantly access any company’s transcript, and with Groq LLM, you can turn that raw text into a sharp, actionable summary in seconds. This pipeline saves hours of reading and ensures you never miss the key results, guidance, or risks hidden in lengthy remarks. Whether you track tech giants like NVIDIA or smaller growth stocks, the process is the same — fast, reliable, and powered by the flexibility of FMP’s data. Summarize Any Stock’s Earnings Call in Seconds Using FMP API was originally published in Coinmonks on Medium, where people are continuing the conversation by highlighting and responding to this story
Share
Medium2025/09/18 14:40
Tom Lee Declares That Ethereum Has Bottomed Out

Tom Lee Declares That Ethereum Has Bottomed Out

Experienced analyst Tom Lee conducted an in-depth analysis of the Ethereum price. Here are some of the highlights from Lee's findings. Continue Reading: Tom Lee
Share
Bitcoinsistemi2026/03/20 19:05

Trending News

More

Trump-backed WLFI  launches AgentPay SDK open-source payment toolkit for AI agents

Summarize Any Stock’s Earnings Call in Seconds Using FMP API

Tom Lee Declares That Ethereum Has Bottomed Out

Trump is 'hurting his own people' — and MAGA is finally noticing: DC insider

Why Gold Plunged More Than 8% This Week Despite Middle East Conflict

Quick Reads

More

What Is OpenClaw? Why This Personal AI Assistant Is Suddenly Everywhere

Liquidity Cycles and Meme Coins: Why BEEG Could Be 2026's Most Asymmetric Bet

Will the 2026 Altcoin Supercycle Ignite a Massive Rally for BEEG?

Why Sui Meme Coins Are Exploding in 2026: The Complete Breakdown Every Crypto Investor Needs to Read

5 Critical Risks of Investing in BEEG You Must Know Before Buying (2026)

Crypto Prices

Bitcoin Logo

Bitcoin

BTC

$70,343.06
$70,343.06$70,343.06

+1.35%

Ethereum Logo

Ethereum

ETH

$2,140.58
$2,140.58$2,140.58

+1.02%

Solana Logo

Solana

SOL

$89.14
$89.14$89.14

+1.72%

XRP Logo

XRP

XRP

$1.4426
$1.4426$1.4426

+0.71%

Tether Gold Logo

Tether Gold

GOLD(XAUT)

$4,676.9
$4,676.9$4,676.9

+1.67%